{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:35:56Z","timestamp":1794638156076,"version":"4.9.1"},"reference-count":133,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Please see the Declaration of Interests in the manuscript."}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2024,5,18]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:p>Chronic cough is a prevalent and challenging condition, with limited treatment options available. The interpretation of clinical trial results for antitussive drugs is complicated by the presence of the placebo response, which can confound outcomes and impede regulatory approval. This review aims to explore the impact of the placebo response on clinical trials for cough medications and elucidate the underlying mechanisms involved. The multifaceted nature of antitussive effects, including pharmacological, psychological\/neurobiological and nonspecific effects, is discussed. Additionally, potential solutions to address the placebo response in future cough medication development, such as strategic study design, appropriate choice of end-points and meticulous patient selection, are proposed. More progress to harness this issue is urgently needed.<\/jats:p>","DOI":"10.1183\/23120541.00335-2024","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T15:52:37Z","timestamp":1719503557000},"page":"00335-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Decoding the impact of the placebo response in clinical trials for chronic cough"],"prefix":"10.1183","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6852-4036","authenticated-orcid":false,"given":"Mengru","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6135-9610","authenticated-orcid":false,"given":"Alyn H.","family":"Morice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"2024102804151432000_10.5.00335-2024.1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00218714"},{"key":"2024102804151432000_10.5.00335-2024.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h5590"},{"key":"2024102804151432000_10.5.00335-2024.3","doi-asserted-by":"crossref","first-page":"s3","DOI":"10.1136\/thorax-2023-220592","article-title":"British Thoracic Society Clinical Statement on chronic cough in adults","volume":"78: Suppl. 6","author":"Parker","year":"2023","journal-title":"Thorax"},{"key":"2024102804151432000_10.5.00335-2024.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00217813"},{"key":"2024102804151432000_10.5.00335-2024.5","doi-asserted-by":"crossref","unstructured":"Zhang M , Morice AH . Unravelling vagal hypersensitivity in chronic cough: a distinct disease. J Physiol 2023; in press [https:\/\/doi.org\/10.1113\/JP284641]","DOI":"10.1113\/JP284641"},{"key":"2024102804151432000_10.5.00335-2024.6","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2003"},{"key":"2024102804151432000_10.5.00335-2024.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2008.08.003"},{"key":"2024102804151432000_10.5.00335-2024.8","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1164\/rccm.201704-0769OC","article-title":"XEN-D0501, a novel transient receptor potential vanilloid 1 antagonist, does not reduce cough in patients with refractory cough","volume":"196","author":"Belvisi","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102804151432000_10.5.00335-2024.9","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00269-2021"},{"key":"2024102804151432000_10.5.00335-2024.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60776-4"},{"key":"2024102804151432000_10.5.00335-2024.11","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/apt.15169","article-title":"Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough","volume":"49","author":"Dong","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2024102804151432000_10.5.00335-2024.12","doi-asserted-by":"publisher","DOI":"10.1378\/chest.15-1271"},{"key":"2024102804151432000_10.5.00335-2024.13","doi-asserted-by":"publisher","DOI":"10.1002\/lary.25978"},{"key":"2024102804151432000_10.5.00335-2024.14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00408-023-00666-y","article-title":"The therapeutic landscape in chronic cough","volume":"202","author":"Smith","year":"2024","journal-title":"Lung"},{"key":"2024102804151432000_10.5.00335-2024.15","doi-asserted-by":"crossref","first-page":"17534666231167716","DOI":"10.1177\/17534666231167716","article-title":"Antitussive efficacy of the current treatment protocol for refractory chronic cough: our real-world experience in a retrospective cohort study","volume":"17","author":"Zhang","year":"2023","journal-title":"Ther Adv Respir Dis"},{"key":"2024102804151432000_10.5.00335-2024.16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200607-892OC"},{"key":"2024102804151432000_10.5.00335-2024.17","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210983.41"},{"key":"2024102804151432000_10.5.00335-2024.18","doi-asserted-by":"crossref","first-page":"913640","DOI":"10.3389\/fpsyt.2022.913640","article-title":"The status and prescription patterns of opioid utilization in a large comprehensive teaching hospital in China according to the anatomical therapeutic chemical classification\/defined daily dose methodology","volume":"13","author":"Fang","year":"2022","journal-title":"Front Psychiatry"},{"key":"2024102804151432000_10.5.00335-2024.19","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.064337"},{"key":"2024102804151432000_10.5.00335-2024.20","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-208843"},{"key":"2024102804151432000_10.5.00335-2024.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61255-1"},{"key":"2024102804151432000_10.5.00335-2024.22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.chest.2019.08.001","article-title":"The neurokinin-1 receptor antagonist orvepitant is a novel antitussive therapy for chronic refractory cough: results from a phase 2 pilot study (VOLCANO-1)","volume":"157","author":"Smith","year":"2020","journal-title":"Chest"},{"key":"2024102804151432000_10.5.00335-2024.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2019.PA600"},{"key":"2024102804151432000_10.5.00335-2024.24","doi-asserted-by":"crossref","first-page":"00546-2021","DOI":"10.1183\/23120541.00546-2021","article-title":"A double-blind randomised placebo-controlled trial investigating the effects of lesogaberan on the objective cough frequency and capsaicin-evoked coughs in patients with refractory chronic cough","volume":"8","author":"Badri","year":"2022","journal-title":"ERJ Open Res"},{"key":"2024102804151432000_10.5.00335-2024.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02348-5"},{"key":"2024102804151432000_10.5.00335-2024.26","unstructured":"Merck provides update on FDA advisory committee meeting evaluating Gefapixant. www.merck.com\/news\/merck-provides-update-on-fda-advisory-committee-meeting-evaluating-gefapixant\/ Date last updated: 17 November 2023. Date last accessed: 12 December 2023."},{"key":"2024102804151432000_10.5.00335-2024.27","unstructured":"Harrington A . The Placebo Effect: an Interdisciplinary Exploration. Cambridge, Harvard University Press, 1999."},{"key":"2024102804151432000_10.5.00335-2024.28","doi-asserted-by":"publisher","DOI":"10.1177\/0020731420979824"},{"key":"2024102804151432000_10.5.00335-2024.29","doi-asserted-by":"crossref","first-page":"2054270416681434","DOI":"10.1177\/2054270416681434","article-title":"Does the model of additive effect in placebo research still hold true? A narrative review","volume":"8","author":"Boehm","year":"2017","journal-title":"JRSM Open"},{"key":"2024102804151432000_10.5.00335-2024.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7004.551"},{"key":"2024102804151432000_10.5.00335-2024.31","doi-asserted-by":"publisher","DOI":"10.1159\/000490354"},{"key":"2024102804151432000_10.5.00335-2024.32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s10194-020-01178-3","article-title":"European Headache Federation recommendations for placebo and nocebo terminology","volume":"21","author":"Mitsikostas","year":"2020","journal-title":"J Headache Pain"},{"key":"2024102804151432000_10.5.00335-2024.33","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1111\/bcp.15345","article-title":"How do they add up? The interaction between the placebo and treatment effect: a systematic review","volume":"88","author":"Boussageon","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2024102804151432000_10.5.00335-2024.34","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1626"},{"key":"2024102804151432000_10.5.00335-2024.35","doi-asserted-by":"crossref","first-page":"e84104","DOI":"10.1371\/journal.pone.0084104","article-title":"Randomised controlled trials may underestimate drug effects: balanced placebo trial design","volume":"9","author":"Lund","year":"2014","journal-title":"PLoS One"},{"key":"2024102804151432000_10.5.00335-2024.36","doi-asserted-by":"publisher","DOI":"10.1006\/pupt.2002.0364"},{"key":"2024102804151432000_10.5.00335-2024.37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702413104"},{"key":"2024102804151432000_10.5.00335-2024.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21179-3"},{"key":"2024102804151432000_10.5.00335-2024.39","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1164\/rccm.202211-2128LE","article-title":"Efficacy and safety of gefapixant for refractory or unexplained chronic cough over 52 weeks","volume":"207","author":"Birring","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102804151432000_10.5.00335-2024.40","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2023.PA3041"},{"key":"2024102804151432000_10.5.00335-2024.41","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-BTSabstracts.7"},{"key":"2024102804151432000_10.5.00335-2024.42","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S2213-2600(19)30471-0","article-title":"Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial","volume":"8","author":"Smith","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102804151432000_10.5.00335-2024.43","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01615-2019"},{"key":"2024102804151432000_10.5.00335-2024.44","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2022.807"},{"key":"2024102804151432000_10.5.00335-2024.45","first-page":"A1019","article-title":"Improvements in cough frequency over 24\u2005hours with BLU-5937, a selective P2X3 antagonist, in patient subgroups defined by baseline awake cough frequencies","volume":"203","author":"Smith","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102804151432000_10.5.00335-2024.46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12931-023-02384-8","article-title":"The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial","volume":"24","author":"Friedrich","year":"2023","journal-title":"Respir Res"},{"key":"2024102804151432000_10.5.00335-2024.47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00408-022-00592-5","article-title":"A randomized, double-blind, placebo-controlled, parallel-group phase 2b trial of P2X3 receptor antagonist sivopixant for refractory or unexplained chronic cough","volume":"201","author":"McGarvey","year":"2023","journal-title":"Lung"},{"key":"2024102804151432000_10.5.00335-2024.48","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00725-2021"},{"key":"2024102804151432000_10.5.00335-2024.49","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210983.41"},{"key":"2024102804151432000_10.5.00335-2024.50","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.21037\/jtd.2017.06.18","article-title":"Theobromine for the treatment of persistent cough: a randomised, multicentre, double-blind, placebo-controlled clinical trial","volume":"9","author":"Morice","year":"2017","journal-title":"J Thorac Dis"},{"key":"2024102804151432000_10.5.00335-2024.51","unstructured":"Axalbion . Press release \u2013 Axalbion announces positive findings from phase 2 clinical study in chronic cough with AX-8, a novel TRPM8 agonist. https:\/\/axalbion.com\/2022\/06\/29\/axalbion-announces-positive\/ Date last updated: 29 June 2022. Date last accessed: 19 March 2024."},{"key":"2024102804151432000_10.5.00335-2024.52","first-page":"A2532","article-title":"Randomized proof-of-concept study of AX-8, a TRPM8 agonist, in refractory or unexplained chronic cough","volume":"207","author":"Smith","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102804151432000_10.5.00335-2024.53","unstructured":"EU Clinical Trials Register . Clinical trial results: a phase 2a, multi-centre, randomised, double-blind, parallel group, placebo-controlled study to evaluate efficacy, safety and tolerability of inhaled GRC 17536, administered for 4 weeks, in patients with refractory chronic cough . https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-002728-17\/results Date last accessed: 15 April 2019."},{"key":"2024102804151432000_10.5.00335-2024.54","unstructured":"BioSpace . Aldeyra therapeutics announces statistically significant reduction in cough frequency in phase 2 clinical trial of ADX-629 in patients with chronic cough. www.biospace.com\/article\/releases\/aldeyra-therapeutics-announces-statistically-significant-reduction-in-cough-frequency-in-phase-2-clinical-trial-of-adx-629-in-patients-with-chronic-cough\/ Date last updated: 27 June 2023. Date last accessed: 19 March 2024."},{"key":"2024102804151432000_10.5.00335-2024.55","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2020.4564"},{"key":"2024102804151432000_10.5.00335-2024.56","unstructured":"Clinical Trials Arena . Menlo reports negative top-line results from serlopitant trial. www.clinicaltrialsarena.com\/company-news\/menlo-reports-negative-top-line-results-phase-ll-trial-serlopitant\/ Date last updated: 10 October 2018. Date last accessed: 20 March 2024."},{"key":"2024102804151432000_10.5.00335-2024.57","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jama.2023.18508","article-title":"Gefapixant for refractory or unexplained chronic cough?","volume":"330","author":"Irwin","year":"2023","journal-title":"JAMA"},{"key":"2024102804151432000_10.5.00335-2024.58","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research . Pulmonary-Allergy Drugs Advisory Committee (PADAC) Meeting. Friday, November 17, 2023. www.fda.gov\/media\/176353\/download Date last accessed: 18 March 2024."},{"key":"2024102804151432000_10.5.00335-2024.59","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00284-2020"},{"key":"2024102804151432000_10.5.00335-2024.60","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1164\/rccm.202304-0643LE","article-title":"What the placebo tells us about chronic cough","volume":"207","author":"Weinberger","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102804151432000_10.5.00335-2024.61","unstructured":"Food and Drug Administration. FDA briefing document NDA# 215010. www.fda.gov\/media\/173850\/download Date last accessed: 16 March 2024."},{"key":"2024102804151432000_10.5.00335-2024.62","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00408-009-9173-3","article-title":"Importance of placebo effect in cough clinical trials","volume":"188","author":"Eccles","year":"2010","journal-title":"Lung"},{"key":"2024102804151432000_10.5.00335-2024.63","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11882-007-0006-2","article-title":"The power of the placebo","volume":"7","author":"Eccles","year":"2007","journal-title":"Curr Allergy Asthma Rep"},{"key":"2024102804151432000_10.5.00335-2024.64","doi-asserted-by":"crossref","unstructured":"Eccles R . Placebo effects in cough. In: Colloca L , Noel J , Franklin PD , et al. , eds. Placebo Effects Through the Lens of Translational Research. Oxford, Oxford University Press, 2023; pp. 134\u2013146.","DOI":"10.1093\/med\/9780197645444.003.0010"},{"key":"2024102804151432000_10.5.00335-2024.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.resp.2005.10.004"},{"key":"2024102804151432000_10.5.00335-2024.66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00408-019-00305-5","article-title":"The powerful placebo effect in cough: relevance to treatment and clinical trials","volume":"198","author":"Eccles","year":"2020","journal-title":"Lung"},{"key":"2024102804151432000_10.5.00335-2024.67","doi-asserted-by":"crossref","unstructured":"Belvisi MG , Hele DJ . Cough Sensors. III. Opioid and cannabinoid receptors on vagal sensory nerves. In: Chung KF , Widdicombe J , eds. Pharmacology and Therapeutics of Cough. Berlin, Springer Berlin Heidelberg, 2009; pp. 63\u201376.","DOI":"10.1007\/978-3-540-79842-2_4"},{"key":"2024102804151432000_10.5.00335-2024.68","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-BTSabstracts.21"},{"key":"2024102804151432000_10.5.00335-2024.69","doi-asserted-by":"crossref","first-page":"EVIDoa2300083","DOI":"10.1056\/EVIDoa2300083","article-title":"Nalbuphine tablets for cough in patients with idiopathic pulmonary fibrosis","volume":"2","author":"Maher","year":"2023","journal-title":"NEJM Evid"},{"key":"2024102804151432000_10.5.00335-2024.70","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11302-022-09877-z","article-title":"ATP, an attractive target for the treatment of refractory chronic cough","volume":"18","author":"Zhang","year":"2022","journal-title":"Purinergic Signal"},{"key":"2024102804151432000_10.5.00335-2024.71","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.21037\/jtd-20-Cough-001","article-title":"The role of ATP in cough hypersensitivity syndrome: new targets for treatment","volume":"12","author":"Zhang","year":"2020","journal-title":"J Thorac Dis"},{"key":"2024102804151432000_10.5.00335-2024.72","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01700-8"},{"key":"2024102804151432000_10.5.00335-2024.73","unstructured":"Merck . Merck receives positive European Union CHMP opinion for gefapixant. www.merck.com\/news\/merck-receives-positive-european-union-chmp-opinion-for-gefapixant\/. Date last updated: 21 July 2023. Date last accessed 18 March 2024."},{"key":"2024102804151432000_10.5.00335-2024.74","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00439-2019"},{"key":"2024102804151432000_10.5.00335-2024.75","unstructured":"Administration USFD . FDA patient-focused drug development guidance series for enhancing the incorporation of the patient's voice in medical product development and regulatory decision making. www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical Date last updated: 14 February 2024. Date last accessed: 18 March 2024."},{"key":"2024102804151432000_10.5.00335-2024.76","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/8755122520954866","article-title":"Treatment of chronic refractory cough in adults: focus on neuromodulators and other therapeutic modalities","volume":"36","author":"O'Hare","year":"2020","journal-title":"J Pharm Technol"},{"key":"2024102804151432000_10.5.00335-2024.77","doi-asserted-by":"publisher","DOI":"10.1177\/0194599812471817"},{"key":"2024102804151432000_10.5.00335-2024.78","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.9.1016"},{"key":"2024102804151432000_10.5.00335-2024.79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/bs.irn.2020.03.029","article-title":"Determinants of placebo effects","volume":"153","author":"Anderson","year":"2020","journal-title":"Int Rev Neurobiol"},{"key":"2024102804151432000_10.5.00335-2024.80","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/bs.irn.2018.07.014","article-title":"Are blue pills better than green? How treatment features modulate placebo effects","volume":"139","author":"Meissner","year":"2018","journal-title":"Int Rev Neurobiol"},{"key":"2024102804151432000_10.5.00335-2024.81","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00043.2012"},{"key":"2024102804151432000_10.5.00335-2024.82","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1984.tb04993.x"},{"key":"2024102804151432000_10.5.00335-2024.83","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2019-100089"},{"key":"2024102804151432000_10.5.00335-2024.84","doi-asserted-by":"crossref","unstructured":"Rotem B-N , Bogdan P , Marta C , et al. Placebo treatment affects brain systems related to affective and cognitive processes, but not nociceptive pain. bioRxiv 2023; preprint [https:\/\/doi.org\/10.1101\/2023.09.21.558825].","DOI":"10.1101\/2023.09.21.558825"},{"key":"2024102804151432000_10.5.00335-2024.85","doi-asserted-by":"crossref","unstructured":"Yetman H , Peci\u00f1a M , Tiwari A , et al. Molecular mechanisms of placebo responses: from genes to pathways. In: Colloca L , Noel J , D Franklin P , et al. ed. Placebo Effects Through the Lens of Translational Research. Oxford, Oxford University Press, 2023; pp. 76\u201389.","DOI":"10.1093\/med\/9780197645444.003.0006"},{"key":"2024102804151432000_10.5.00335-2024.86","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201306-1079OC"},{"key":"2024102804151432000_10.5.00335-2024.87","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41598-024-51477-x","article-title":"Neural substrates of cough control during coughing","volume":"14","author":"Sugi","year":"2024","journal-title":"Sci Rep"},{"key":"2024102804151432000_10.5.00335-2024.88","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00408-020-00390-x","article-title":"What is the role of over 100 excipients in over the counter (OTC) cough medicines?","volume":"198","author":"Eccles","year":"2020","journal-title":"Lung"},{"key":"2024102804151432000_10.5.00335-2024.89","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.262790"},{"key":"2024102804151432000_10.5.00335-2024.90","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2217\/pgs-2019-0001","article-title":"Systems pharmacogenomics - gene, disease, drug and placebo interactions: a case study in COMT","volume":"20","author":"Hall","year":"2019","journal-title":"Pharmacogenomics"},{"key":"2024102804151432000_10.5.00335-2024.91","doi-asserted-by":"crossref","first-page":"775386","DOI":"10.3389\/fpain.2021.775386","article-title":"Genomic effects associated with response to placebo treatment in a randomized trial of irritable bowel syndrome","volume":"2","author":"Wang","year":"2021","journal-title":"Front Pain Res (Lausanne)"},{"key":"2024102804151432000_10.5.00335-2024.92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048135"},{"key":"2024102804151432000_10.5.00335-2024.93","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3976"},{"key":"2024102804151432000_10.5.00335-2024.94","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00210-022-02280-w","article-title":"Placebo: a brief updated review","volume":"395","author":"Pardo-Cabello","year":"2022","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2024102804151432000_10.5.00335-2024.95","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.shpsa.2020.12.008","article-title":"Francis Galton's regression towards mediocrity and the stability of types","volume":"86","author":"Krashniak","year":"2021","journal-title":"Stud History Philos Sci Part A"},{"key":"2024102804151432000_10.5.00335-2024.96","doi-asserted-by":"publisher","DOI":"10.1097\/01.psy.0000155667.59662.92"},{"key":"2024102804151432000_10.5.00335-2024.97","doi-asserted-by":"publisher","DOI":"10.1002\/da.10134"},{"key":"2024102804151432000_10.5.00335-2024.98","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamapsychiatry.2021.3204","article-title":"Association of single-blind placebo run-in periods with the placebo response in randomized clinical trials of antidepressants: a systematic review and meta-analysis","volume":"79","author":"Scott","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"2024102804151432000_10.5.00335-2024.99","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-10-27"},{"key":"2024102804151432000_10.5.00335-2024.100","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026478"},{"key":"2024102804151432000_10.5.00335-2024.101","doi-asserted-by":"publisher","DOI":"10.1159\/000069738"},{"key":"2024102804151432000_10.5.00335-2024.102","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/sim.7635","article-title":"Sequential parallel comparison design with binary and time-to-event outcomes","volume":"37","author":"Silverman","year":"2018","journal-title":"Stat Med"},{"key":"2024102804151432000_10.5.00335-2024.103","doi-asserted-by":"publisher","DOI":"10.1177\/0962280211431023"},{"key":"2024102804151432000_10.5.00335-2024.104","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2011.04.006"},{"key":"2024102804151432000_10.5.00335-2024.105","doi-asserted-by":"publisher","DOI":"10.1177\/1740774507081217"},{"key":"2024102804151432000_10.5.00335-2024.106","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1002\/sim.8288","article-title":"Comparison of novel methods in two-way enriched clinical trial design","volume":"38","author":"Liu","year":"2019","journal-title":"Stat Med"},{"key":"2024102804151432000_10.5.00335-2024.107","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/sim.6116","article-title":"A sequential enriched design for target patient population in psychiatric clinical trials","volume":"33","author":"Chen","year":"2014","journal-title":"Stat Med"},{"key":"2024102804151432000_10.5.00335-2024.108","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1038\/npp.2017.106","article-title":"A randomized, double-blind, placebo-controlled, sequential parallel comparison design trial of adjunctive riluzole for treatment-resistant major depressive disorder","volume":"42","author":"Mathew","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"2024102804151432000_10.5.00335-2024.109","unstructured":"Food and Drug Administration . Major depressive disorder: developing drugs for treatment. www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/major-depressive-disorder-developing-drugs-treatment Date last updated: 18 October 2019. Date last accessed: 29 March 2024."},{"key":"2024102804151432000_10.5.00335-2024.110","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/bimj.201800394","article-title":"Sequential parallel comparison design for \u201cgold standard\u201d noninferiority trials with a prespecified margin","volume":"61","author":"Homma","year":"2019","journal-title":"Biom J"},{"key":"2024102804151432000_10.5.00335-2024.111","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/19466315.2021.1924257","article-title":"A test for treatment effects based on the exact distribution of an ordinary least-square estimator in sequential parallel comparison design","volume":"14","author":"Tsuchida","year":"2022","journal-title":"Stat Biopharm Res"},{"key":"2024102804151432000_10.5.00335-2024.112","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202678.220"},{"key":"2024102804151432000_10.5.00335-2024.113","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00057407"},{"key":"2024102804151432000_10.5.00335-2024.114","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.21037\/jtd-22-874","article-title":"Chronic cough - the limitation and advances in assessment techniques","volume":"14","author":"Zhang","year":"2022","journal-title":"J Thorac Dis"},{"key":"2024102804151432000_10.5.00335-2024.115","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-017-9996-2"},{"key":"2024102804151432000_10.5.00335-2024.116","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.5415\/apallergy.2022.12.e19","article-title":"Long-COVID severe refractory cough: discussion of a case with 6-week longitudinal cough characterization","volume":"12","author":"Kang","year":"2022","journal-title":"Asia Pac Allergy"},{"key":"2024102804151432000_10.5.00335-2024.117","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00408-022-00559-6","article-title":"The statistics of counting coughs: easy as 1, 2, 3?","volume":"200","author":"Rudd","year":"2022","journal-title":"Lung"},{"key":"2024102804151432000_10.5.00335-2024.118","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00408-023-00647-1","article-title":"Feasibility and utility of a smartphone application-based longitudinal cough monitoring in chronic cough patients in a real-world setting","volume":"201","author":"Lee","year":"2023","journal-title":"Lung"},{"key":"2024102804151432000_10.5.00335-2024.119","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00279-2022"},{"key":"2024102804151432000_10.5.00335-2024.120","unstructured":"Food and Drug Administration . Development of non-opioid analgesics for acute pain: draft guidance for industry. www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/development-non-opioid-analgesics-acute-pain-draft-guidance-industry Date last updated: 16 February 2022. Date last accessed: 22 March 2024"},{"key":"2024102804151432000_10.5.00335-2024.121","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s41687-018-0053-6","article-title":"Response scale selection in adult pain measures: results from a literature review","volume":"2","author":"Safikhani","year":"2017","journal-title":"J Patient Rep Outcomes"},{"key":"2024102804151432000_10.5.00335-2024.122","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1016\/j.jaip.2023.08.046","article-title":"Patient global impression of severity scale in chronic cough: validation and formulation of symptom severity categories","volume":"11","author":"Rhatigan","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102804151432000_10.5.00335-2024.123","unstructured":"Food and Drug Administration . Multiple endpoints in clinical trials guidance for industry. www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/multiple-endpoints-clinical-trials-guidance-industry Date last updated: 16 April 2024. Date last accessed: 22 March 2024"},{"key":"2024102804151432000_10.5.00335-2024.124","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12151"},{"key":"2024102804151432000_10.5.00335-2024.125","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.clnu.2024.03.017","article-title":"Assessing \u2018response\u2019 to the low-FODMAP diet in irritable bowel syndrome: should we be reporting harder primary endpoints?","volume":"43","author":"Conley","year":"2024","journal-title":"Clin Nutr"},{"key":"2024102804151432000_10.5.00335-2024.126","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.93.06101449"},{"key":"2024102804151432000_10.5.00335-2024.127","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-010-9272-1"},{"key":"2024102804151432000_10.5.00335-2024.128","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00408-021-00452-8","article-title":"On chronic cough diagnosis, classification, and treatment","volume":"199","author":"Morice","year":"2021","journal-title":"Lung"},{"key":"2024102804151432000_10.5.00335-2024.129","unstructured":"Food and Drug Administration . Adjusting for covariates in randomized clinical trials for drugs and biological products: guidance for industry. www.fda.gov\/media\/148910\/download Date last updated: May 2023. Date last accessed: 22 March 2024."},{"key":"2024102804151432000_10.5.00335-2024.130","unstructured":"The European Agency for the Evaluation of Medicinal Products . Points to consider on adjustment for baseline covariates. www.ema.europa.eu\/en\/documents\/scientific-guideline\/points-consider-adjustment-baseline-covariates_en.pdf. Date last updated 22 May 2003. Date last accedssed: 22 March 2024."},{"key":"2024102804151432000_10.5.00335-2024.131","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41386-023-01573-9","article-title":"Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder","volume":"48","author":"Tobe","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"2024102804151432000_10.5.00335-2024.132","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/bs.irn.2020.04.002","article-title":"Strategies to minimize placebo effects in research investigations","volume":"153","author":"Rodrigues","year":"2020","journal-title":"Int Rev Neurobiol"},{"key":"2024102804151432000_10.5.00335-2024.133","doi-asserted-by":"crossref","first-page":"e2243848","DOI":"10.1001\/jamanetworkopen.2022.43848","article-title":"Placebo response and media attention in randomized clinical trials assessing cannabis-based therapies for pain: a systematic review and meta-analysis","volume":"5","author":"Gedin","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00335-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:38:09Z","timestamp":1740375489000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00335-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":133,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10,28]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1183\/23120541.00335-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00335-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]}}}